Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
06/2000
06/21/2000EP1009811A2 New tissue-specific calpaines, their production and their use
06/21/2000EP1009769A1 N-terminal modifications of rantes and methods of use
06/21/2000EP1009767A1 HUMAN DEFENSIN DEF-X, GENE AND DNAc, COMPOSITION CONTAINING SAME AND DIAGNOSTIC AND THERAPEUTIC APPLICATIONS
06/21/2000EP1009764A1 VACCINE COMPOSITIONS COMPRISING THE $i(HELICOBACTER PYLORI) FlgE POLYPEPTIDE
06/21/2000EP1009763A1 Synthetic hepatitis c genes
06/21/2000EP1009760A2 Peroxisome-associated polypeptide, nucleotide sequence encoding said polypeptide and their uses in the diagnosis and/or the treatment of lung injuries and diseases, and of oxidative stress-related disorders
06/21/2000EP1009752A1 Novel molecules of the tango-77 related protein family and uses thereof
06/21/2000EP1009737A2 Sulfonylamino substituted hydroxamic acid derivatives as metalloprotease inhibitors
06/21/2000EP1009732A2 1-amino-alkylcyclohexane nmda receptor antagonists
06/21/2000EP1009443A1 priA POLYPEPTIDES
06/21/2000EP1009441A1 Method for the treatment of grafts
06/21/2000EP1009440A1 Method for inhibiting immunostimulatory dna associated responses
06/21/2000EP1009433A1 Therapeutic composition and method of treatment
06/21/2000EP1009432A1 Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses
06/21/2000EP1009431A1 Human tumor necrosis factor receptor-like 2 (tr2) antibodies
06/21/2000EP1009430A1 Vaccines
06/21/2000EP1009429A1 Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
06/21/2000EP1009426A1 Method for treating a subject suffering from conditions associated with an extracellular zinc sphingomyelinase
06/21/2000EP1009419A2 Graminae pollen allergen mutants for specific immunotherapy, and production and use of the same
06/21/2000EP1009413A2 Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation
06/21/2000EP1009405A1 Pyrrolidine and piperidine modulators of chemokine receptor activity
06/21/2000EP0820304B1 Chlamydia vaccines
06/21/2000DE19858331A1 Tricyclische Stickstoffheterocyclen als PDE IV Inhibitoren Tricyclic nitrogen heterocycles as PDE IV inhibitors
06/21/2000CN1257538A Short peptides which selectively modulate the activity of serine/threonine kinases
06/21/2000CN1257507A Novel triptolide derivatives useful in the treatment of autoimmune diseases
06/21/2000CN1257503A 2-amino-7-(1-substituted-2-hydroxyethyl)-3,5-dihydro-pyrrolo (3,2-D] pyrimidine-4-ones
06/21/2000CN1257481A Novel pyridine derivatives and pharmaceutical compositions containing them
06/21/2000CN1257431A Chemically and thermally stable norastemizole formulations
06/21/2000CN1257426A Use of fumaric acid derivatives
06/21/2000CN1053665C 2,4-diaryl-1,3-dithiolanes, 2,4-diaryl-1,3-dioxolanes, 2,4-diaryl-1,3-oxathiolanes derivant
06/21/2000CN1053662C New tricyclic amide compounds, processes for their preparation and the pharmaceutical compositions containing same
06/20/2000US6077950 Adjusting efficiency of animals antibody response by administering animal a polypeptide to activate antibody response
06/20/2000US6077948 Mediators of chronic allograft rejection (AIF-1) and DNA encoding them
06/20/2000US6077851 Quinoline derivatives
06/20/2000US6077833 Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
06/20/2000US6077828 Method for the prevention and treatment of cachexia and anorexia
06/20/2000US6077518 Cloning of mite allergens
06/20/2000US6077517 House dust mite allergen, Der p VII, and uses thereof
06/20/2000US6077509 Given amino acid sequences that are immunodominant in humans suffering from multiple sclerosis
06/15/2000WO2000034494A1 A recombinant vector expressing multiple costimulatory molecules and uses thereof
06/15/2000WO2000034485A2 Beta-1,3-galactosyltransferase homologs
06/15/2000WO2000034477A2 Neuron-associated proteins
06/15/2000WO2000034468A2 Muc-1 antagonists and methods of treating immune disorders
06/15/2000WO2000034467A1 Cancer cell vaccine
06/15/2000WO2000034447A2 Human ubiquitin ligase e3 for the modulation of nf-kappa b
06/15/2000WO2000034444A2 Method and composition for preserving viruses
06/15/2000WO2000034334A1 DNA ENCODING A MAMMALIAN RECEPTOR (fb41a) AND USES THEREOF
06/15/2000WO2000034313A1 Procollagen c-proteinase inhibitors
06/15/2000WO2000034303A1 METHODS OF MODULATING TUMOR NECROSIS FACTOR α-INDUCED EXPRESSION OF CELL ADHESION MOLECULES
06/15/2000WO2000034296A2 Conjugates comprising galactose alpha 1,3 galactosyl epitopes and methods of using same
06/15/2000WO2000034294A2 Tumor necrosis factor receptor homologue-1 ('trh1')
06/15/2000WO2000034281A1 Methotrexate derivatives
06/15/2000WO2000034250A1 2,4-dioxo-5-arylidenimino-1,3-pyrimidines
06/15/2000WO2000034248A1 New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents
06/15/2000WO2000033878A2 Stabilization of macrolides
06/15/2000WO2000033876A1 Formulation with an improved therapeutic range, containing nucleotide synthesis inhibitors
06/15/2000WO2000033870A2 New cancer treatments
06/15/2000WO2000033869A2 Use of human prostrate cell lines in cancer treatment
06/15/2000WO2000033862A1 Self-emulsifying compositions for drugs poorly soluble in water
06/15/2000WO2000033838A1 Vitronectin receptor antagonist
06/15/2000WO2000033834A1 Use of isatin derivatives as ion channel activating agents
06/15/2000WO2000033817A1 Phospholipid compositions
06/15/2000WO2000033662A1 Baby food stimulating growth of the thymus
06/15/2000WO2000015231A8 Adenosine a3 receptor modulators
06/15/2000WO2000012678A3 Staphylococcus aureus genes and polypeptides
06/15/2000WO2000010600A3 Activation and protection of t-cells (cd4+ and cd8+) using an h¿2? receptor agonist and other t-cell activating agents
06/15/2000WO2000006531A3 Nitric esters and nitrate salts of specific drugs
06/15/2000WO2000005374A3 Molecules associated with cell proliferation
06/15/2000WO2000005254A3 Novel peptides for use in immunotherapy of autoimmune diseases
06/15/2000WO2000001821A3 Neurotransmission associated proteins
06/15/2000WO1999066051A3 Nek-related and bub1-related protein kinases
06/15/2000WO1999061056A9 Methods and products for inducing mucosal immunity
06/15/2000WO1999061052A9 Oral immunization with papillomavirus virus-like particles
06/15/2000DE19857009A1 Zubereitung mit verbesserter therapeutischer Breite, enthaltend Nukleotidsyntheseinhibitoren Preparation with improved therapeutic index containing nucleotide synthesis
06/15/2000DE19856789A1 Thymuswachstumsstimulierende Säuglingsnahrung Thymuswachstumsstimulierende baby food
06/15/2000CA2732620A1 Crystalline form of 40-o-(2-hydroxy-ethyl) rapamycin and process for preparation thereof
06/15/2000CA2678259A1 A recombinant vector expressing multiple costimulatory molecules and uses thereof
06/15/2000CA2651609A1 Crystalline form of 40-o- (2-hydroxy-ethyl) rapamycin and process for preparation thereof
06/15/2000CA2363310A1 2,4-dioxo-5-arylidenimino-1,3-pyrimidines
06/15/2000CA2354644A1 Muc-1 antagonists and methods of treating immune disorders
06/15/2000CA2354612A1 Tumor necrosis factor receptor homologue-1 ("trh1")
06/15/2000CA2354266A1 Formulation with an improved therapeutic range, containing nucleotide synthesis inhibitors
06/15/2000CA2354233A1 Self-emulsifying compositions for drugs poorly soluble in water
06/15/2000CA2354188A1 Cancer cell vaccine
06/15/2000CA2354026A1 Beta-1,3-galactosyltransferase homologs
06/15/2000CA2353839A1 Methotrexate derivatives
06/15/2000CA2353797A1 Neuron-associated proteins
06/15/2000CA2353620A1 Methods and formulations for reducing circulating antibodies
06/15/2000CA2353415A1 Vitronectin receptor antagonist
06/15/2000CA2352758A1 Conjugates comprising galactose alpha 1,3 galactosyl epitopes and methods of using same
06/15/2000CA2352740A1 Procollagen c-proteinase inhibitors
06/15/2000CA2352178A1 Phospholipid compositions
06/15/2000CA2351890A1 Method and composition for preserving viruses
06/15/2000CA2349616A1 New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents
06/14/2000EP1008649A2 Antisense-oligonucleotides for the treatment of immuno-suppressive effects of transforming growth factor-b2(TGF-b2)
06/14/2000EP1008345A1 Antiallergic agents
06/14/2000EP1007720A1 Dendritic cell hybrids
06/14/2000EP1007678A1 Kringle1
06/14/2000EP1007625A1 Immunity enhancing lactic acid bacteria
06/14/2000EP1007569A1 STIMULATION OF AN IMMUNE RESPONSE WITH ANTIBODIES LABELED WITH THE $g(a)-GALACTOSYL EPITOPE
1 ... 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 ... 1172